title: Twenty-four years of follow-up for a Hanford plutonium wound case.
abstract: A 1985 plutonium puncture wound resulted in the initial deposition of 48 kBq of transuranic alpha activity, primarily 239+240Pu and 241Am, in a worker's right index finger. Surgical excisions in the week following reduced the long-term residual wound activity to 5.4 kBq, and 164 DTPA chelation therapy administrations over 17 mo resulted in urinary excretion of about 7 kBq. The case was published in 1988, but now 24 y of follow-up data are available. Annual bioassays have included in-vivo measurements of 241Am in the wound, skeleton, liver, lung, and axillary lymph nodes, and urinalyses for plutonium and 241Am. These measurements have shown relatively stable levels of 241Am at the wound site, with gradually increasing amounts of 241Am detected in the skeleton. Liver measurements have shown erratic detection of 241Am, and the lung measurements indicate Am but as interference from activity in the axillary lymph nodes and skeleton rather than activity in the lung. Urine excretion of Pu since termination of chelation therapy has typically ranged from 10 to 20 mBq d, with Am excretion about 10% of that for 239+240Pu. Annual routine medical exams have not identified any adverse health effects associated with the intake.
authors.affiliation: Pacific Northwest National Laboratory, Richland, WA 99352, USA. gene.carbaugh@pnl.gov
authors.forename: Eugene H
authors.initials: EH
authors.lastname: Carbaugh
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Lynch
authors.forename: Cheryl L
authors.initials: CL
authors.lastname: Antonio
authors.forename: Fernando
authors.initials: F
authors.lastname: Medina-Del Valle
mesh_terms: D000062:Accidents, Occupational; D000328:Adult; D000576:Americium / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000652:urine; D001681:Biological Assay; D001822:Body Burden; D015913:Chelation Therapy; D005385:Fingers / Q000601:surgery; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D009688:Nuclear Reactors; D016273:Occupational Exposure / Q000009:adverse effects / Q000032:analysis*; D004369:Pentetic Acid / Q000008:administration & dosage; D011005:Plutonium / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000652:urine; D011832:Radiation Injuries / Q000139:chemically induced / Q000378:metabolism* / Q000517:prevention & control / Q000628:therapy; D013997:Time Factors; D014018:Tissue Distribution; D014861:Washington; D014950:Wounds, Penetrating / Q000378:metabolism* / Q000601:surgery / Q000628:therapy
chemical_list: D011005:Plutonium; D004369:Pentetic Acid; D000576:Americium